CRISM Therapeutics Corporation (AIM:CRTX)
London flag London · Delayed Price · Currency is GBP · Price in GBX
13.56
-0.44 (-3.14%)
Feb 13, 2026, 8:05 AM GMT

CRISM Therapeutics Balance Sheet

Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
0.351.2802.894.932.04
Cash & Short-Term Investments
0.351.2802.894.932.04
Cash Growth
-81.26%128100.00%-99.97%-41.42%141.49%580.01%
Accounts Receivable
--0.01---
Other Receivables
1.20.05--0.080
Receivables
1.20.050.01-0.080
Inventory
-----0.15
Prepaid Expenses
-0.36-0.05-0.11
Other Current Assets
---20.9118.05-
Total Current Assets
1.551.690.0123.8523.072.31
Property, Plant & Equipment
0.040.050.07--0.33
Long-Term Investments
-----3.85
Other Intangible Assets
0.140.070.05--17.24
Total Assets
1.741.820.1323.8523.0723.73
Accounts Payable
0.110.03-0.110.710.22
Accrued Expenses
0.150.140.010.51-0.44
Short-Term Debt
--0.3---
Current Portion of Long-Term Debt
--0.09---
Other Current Liabilities
0.170.170.020.150.120
Total Current Liabilities
0.430.340.420.760.830.67
Long-Term Debt
--0.3---
Other Long-Term Liabilities
-----0.1
Total Liabilities
0.430.340.730.760.830.77
Common Stock
66.2366.23-67.0559.4158.92
Additional Paid-In Capital
3.363.36-3.553.163.13
Retained Earnings
-2.14-1.21-0.6-33.64-27.71-26.72
Comprehensive Income & Other
-66.14-66.9--13.88-12.63-12.38
Shareholders' Equity
1.311.48-0.623.0922.2422.96
Total Liabilities & Equity
1.741.820.1323.8523.0723.73
Total Debt
--0.7---
Net Cash (Debt)
0.351.28-0.72.894.932.04
Net Cash Growth
-81.26%---41.42%141.49%580.01%
Net Cash Per Share
0.010.04-43.500.330.570.31
Filing Date Shares Outstanding
39.3432.688.718.718.628.62
Total Common Shares Outstanding
39.3432.688.718.718.628.62
Working Capital
1.131.35-0.4123.0922.241.64
Book Value Per Share
0.030.05-0.072.652.582.66
Tangible Book Value
1.171.4-0.6523.0922.245.72
Tangible Book Value Per Share
0.030.04-0.072.652.580.66
Machinery
-0.160.16--3.05
Source: S&P Global Market Intelligence. Standard template. Financial Sources.